

BioRestorative Therapies, Inc.  
 Form 4  
 October 08, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Silva Francisco

2. Issuer Name and Ticker or Trading Symbol  
 BioRestorative Therapies, Inc.  
 [BRTX]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 555 HERITAGE DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 10/04/2013

\_\_\_\_ Director  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 VP of Research and Development

JUPITER, FL 33458  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |     |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----|-------|
|                                 |                                      |  |                                | (A) or (D)  | Code  | V  | Amount                            | (D) | Price |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any | 4. Transaction Code | 5. Number of Derivative Securities | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|

## Edgar Filing: BioRestorative Therapies, Inc. - Form 4

| (Instr. 3)      | Price of<br>Derivative<br>Security | (Month/Day/Year) | (Instr. 8)  |         | Date<br>Exercisable | Expiration<br>Date | Title           | Amount<br>Number<br>Shares |        |
|-----------------|------------------------------------|------------------|---|---------|---------------------|--------------------|-----------------|----------------------------|--------|
|                 |                                    |                  | Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and<br>5) | Code V  |                     |                    |                 |                            |        |
| Stock<br>Option | \$ 0.5                             |                  |   |         | (1)                 | 04/04/2021         | Common<br>Stock | 80,000                     |        |
| Stock<br>Option | \$ 1.25                            |                  |   |         |                     | 06/24/2011         | 06/23/2021      | Common<br>Stock            | 3,000  |
| Stock<br>Option | \$ 1                               |                  |   |         |                     | 11/16/2011         | 11/15/2021      | Common<br>Stock            | 20,000 |
| Stock<br>Option | \$ 1.05                            |                  |   |         | (2)                 | 02/09/2022         | Common<br>Stock | 40,000                     |        |
| Stock<br>Option | \$ 1.4                             |                  |   |         | (3)                 | 05/02/2022         | Common<br>Stock | 150,000                    |        |
| Stock<br>Option | \$ 1.5                             |                  |   |         | (4)                 | 12/07/2022         | Common<br>Stock | 80,000                     |        |
| Stock<br>Option | \$ 0.6                             | 10/04/2013       | A   | 100,000 | (5)                 | 10/04/2023         | Common<br>Stock | 100,000                    |        |

## Reporting Owners

| Reporting Owner Name / Address                             | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| Silva Francisco<br>555 HERITAGE DRIVE<br>JUPITER, FL 33458 |               |           | VP of Research and Development |       |

## Signatures

Francisco Silva                      10/08/2013

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option is exercisable to the extent of 40,000 shares on each of April 5, 2011 and April 5, 2012.

(2) The option is exercisable to the extent of 20,000 shares on each of February 10, 2012 and February 10, 2013.

The option is exercisable to the extent of 10,000 shares on each of May 3, 2013, 2014 and 2015, is exercisable to the extent of 20,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 100,000 shares subject to the satisfaction of certain conditions.

(4) The option is exercisable to the extent of 40,000 shares on each of December 7, 2012 and December 7, 2013.

(5) The option is exercisable to the extent of 50,000 shares on each of October 4, 2013 and October 4, 2014.

## Edgar Filing: BioRestorative Therapies, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.